Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Caris Life Sciences,�Inc. (CAI) had Cost of Goods Sold of $84.12M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$263.71M |
|
$-0.64M |
|
|
Cost of Goods Sold |
$84.12M |
$179.60M |
|
$236.79M |
|
$26.93M |
|
$-27.54M |
|
$-0.61M |
|
$-0.61M |
|
$-0.64M |
|
$-0.64M |
|
$-0.64M |
|
$-0.64M |
|
$26.93M |
|
$33.76M |
|
282.89M |
|
282.89M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$1.06B |
|
$95.72M |
|
$171.79M |
|
$1.23B |
|
$191.44M |
|
$392.97M |
|
$446.45M |
|
$637.89M |
|
$591.73M |
|
$572.39M |
|
$591.73M |
|
282.58M |
|
| Cash Flow Statement Financials | |
$61.35M |
|
$-132.53M |
|
$-36.08M |
|
$800.04M |
|
$692.75M |
|
$-107.30M |
|
$38.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.53 |
|
-- |
|
-- |
|
0.40 |
|
0.66 |
|
68.10% |
|
10.21% |
|
10.21% |
|
-- |
|
-0.23% |
|
-0.24% |
|
$28.94M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.68 |
|
2.26 |
|
39.89 |
|
-0.11% |
|
-0.11% |
|
-0.05% |
|
-0.06% |
|
$2.09 |
|
$0.10 |
|
$0.22 |
|